FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2081875144> ?p ?o ?g. }

• W2081875144 endingPage "448" @default.
• W2081875144 startingPage "447" @default.
• W2081875144 abstract "Editor—Levosimendan, a novel calcium sensitizer and K-ATP channel opener, has been used in a variety of clinical settings, including acute decompensated and low output heart failure, adult respiratory distress syndrome, ischaemic myocardial stunning, and cardiac surgery. We would like to report our use of levosimendan (0.1–0.2 μg kg−1min−1) over 24 h as rescue therapy in six patients with refractory septic shock,1American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.Crit Care Med. 1992; 20: 864-874Crossref PubMed Scopus (4864) Google Scholar despite conventional resuscitation.2Dellinger RP Carlet JM Masur H et al.For the Surviving Sepsis Campaign Management Guidelines Committee: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shockCrit Care Med. 2004; 32: 858-873Crossref PubMed Scopus (2550) Google Scholar Cardio-respiratory, metabolic, and outcome data were collected and reviewed. In this group of patients, post-levosimendan infusion, there was a trend towards increased mean arterial pressure, improved arterial oxygen partial pressure: fractional inspired oxygen ratio, increased cardiac index, reduced base excess, improved pH, and reduced lactate. There was also a reduction in heart rate, pulmonary vascular resistance index, and systemic vascular resistance index. Catecholamine requirements were reduced in all patients. There were no adverse effects associated with the use of levosimendan in this group and despite predicted 28 day mortality by APACHE II score being approximately 60%, all but one of the patients survived to leave hospital. There are data emerging to support the use of levosimendan in septic myocardial depression3Morelli A De Castro S Teboul J-L et al.Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression.Intensive Care Med. 2005; 31: 638-644Crossref PubMed Scopus (229) Google Scholar and its role in reducing the incidence of ARDS4Morelli A Teboul J-L Maggiore SM et al.Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study.Crit Care Med. 2006; 34: 2287-2293Crossref PubMed Scopus (185) Google Scholar in sepsis. There are also data from experimental models that levosimendan may have a protective role in endotoxaemic acute renal failure5Zager RA Johnson AC Lund S Hanson SY Abrass CK Levosimendan protects against experimental endotoxemic acute renal failure.Am J Physiol Renal Physiol. 2006; 290: 1453-1462Crossref PubMed Scopus (112) Google Scholar and an immuno-modulatory effect via pro-inflammatory cytokine level reduction.6Avgeropoulou C Andreadou I Markantonis-Kyroudis S et al.The Ca2+-sensitiser levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine.Eur J Heart Failure. 2005; 7: 882-887Crossref PubMed Scopus (91) Google Scholar Our series of septic shock patients treated with levosimendan differs from previous series, in that its use as rescue therapy was not limited to those with previously normal left ventricular function or to those in whom dobutamine had been ineffective. We did not limit our use of levosimendan to those with low output cardiac states, but rather we used it as rescue therapy in those whose catecholamine requirements remained high, despite adequate fluid resuscitation. Our observations appear to support the growing interest in the use of levosimendan in septic shock as a safe and potentially useful adjunct to conventional therapy. We are currently undertaking a prospective, randomized, placebo-controlled trial to further investigate the use of levosimendan as rescue therapy in refractory septic shock as an adjunct to conventional therapy." @default.
• W2081875144 created "2016-06-24" @default.
• W2081875144 creator A5045736370 @default.
• W2081875144 creator A5060214405 @default.
• W2081875144 date "2007-09-01" @default.
• W2081875144 modified "2023-09-30" @default.
• W2081875144 title "Levosimendan in septic shock: a case series" @default.
• W2081875144 cites W1992536611 @default.
• W2081875144 cites W2064927551 @default.
• W2081875144 cites W2077733292 @default.
• W2081875144 cites W2108130826 @default.
• W2081875144 cites W2599527603 @default.
• W2081875144 cites W4245690870 @default.
• W2081875144 doi "https://doi.org/10.1093/bja/aem225" @default.
• W2081875144 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17702832" @default.
• W2081875144 hasPublicationYear "2007" @default.
• W2081875144 type Work @default.
• W2081875144 sameAs 2081875144 @default.
• W2081875144 citedByCount "26" @default.
• W2081875144 countsByYear W20818751442012 @default.
• W2081875144 countsByYear W20818751442014 @default.
• W2081875144 countsByYear W20818751442015 @default.
• W2081875144 countsByYear W20818751442018 @default.
• W2081875144 countsByYear W20818751442020 @default.
• W2081875144 crossrefType "journal-article" @default.
• W2081875144 hasAuthorship W2081875144A5045736370 @default.
• W2081875144 hasAuthorship W2081875144A5060214405 @default.
• W2081875144 hasBestOaLocation W20818751441 @default.
• W2081875144 hasConcept C126322002 @default.
• W2081875144 hasConcept C139940330 @default.
• W2081875144 hasConcept C164705383 @default.
• W2081875144 hasConcept C177713679 @default.
• W2081875144 hasConcept C2777335384 @default.
• W2081875144 hasConcept C2777628635 @default.
• W2081875144 hasConcept C2778198053 @default.
• W2081875144 hasConcept C2778384902 @default.
• W2081875144 hasConcept C2779295919 @default.
• W2081875144 hasConcept C31861589 @default.
• W2081875144 hasConcept C58245268 @default.
• W2081875144 hasConcept C71924100 @default.
• W2081875144 hasConcept C84393581 @default.
• W2081875144 hasConceptScore W2081875144C126322002 @default.
• W2081875144 hasConceptScore W2081875144C139940330 @default.
• W2081875144 hasConceptScore W2081875144C164705383 @default.
• W2081875144 hasConceptScore W2081875144C177713679 @default.
• W2081875144 hasConceptScore W2081875144C2777335384 @default.
• W2081875144 hasConceptScore W2081875144C2777628635 @default.
• W2081875144 hasConceptScore W2081875144C2778198053 @default.
• W2081875144 hasConceptScore W2081875144C2778384902 @default.
• W2081875144 hasConceptScore W2081875144C2779295919 @default.
• W2081875144 hasConceptScore W2081875144C31861589 @default.
• W2081875144 hasConceptScore W2081875144C58245268 @default.
• W2081875144 hasConceptScore W2081875144C71924100 @default.
• W2081875144 hasConceptScore W2081875144C84393581 @default.
• W2081875144 hasIssue "3" @default.
• W2081875144 hasLocation W20818751441 @default.
• W2081875144 hasLocation W20818751442 @default.
• W2081875144 hasOpenAccess W2081875144 @default.
• W2081875144 hasPrimaryLocation W20818751441 @default.
• W2081875144 hasRelatedWork W2015335843 @default.
• W2081875144 hasRelatedWork W2067361909 @default.
• W2081875144 hasRelatedWork W2069220534 @default.
• W2081875144 hasRelatedWork W2151693723 @default.
• W2081875144 hasRelatedWork W2292699211 @default.
• W2081875144 hasRelatedWork W2383399822 @default.
• W2081875144 hasRelatedWork W2400476789 @default.
• W2081875144 hasRelatedWork W2909734694 @default.
• W2081875144 hasRelatedWork W3032278371 @default.
• W2081875144 hasRelatedWork W3213616518 @default.
• W2081875144 hasVolume "99" @default.
• W2081875144 isParatext "false" @default.
• W2081875144 isRetracted "false" @default.
• W2081875144 magId "2081875144" @default.
• W2081875144 workType "article" @default.